THE EFFICACY OF SUNITINIB IN THE SECOND-LINE THERAPY OF GASTROINTESTINAL STROMAL TUMORS (GIST) DEPENDING ON THE MUTATION STATUS OF GENE KIT

Koroleva Alexandra Mikhailovna, Kogonia Lali Mikhailovna

The article presents the results of a clinical trial of the efficacy of sunitinib in the second-line therapy of gastrointestinal stromal tumors (GIST) depending on the mutation status of the gene KIT (n=72). Disease control (partial response + stabilization > 6 months) was achieved in 41 (56.3%) of 72 patients. With a mutation in exon 11 of the gene KIT. Disease control was achieved in 40% of patients with a mutation in exon 11 of the gene KIT in 84.6% of patients with a mutation in exon 9 of the gene KIT (p= 0.005133) and in 85.7% of patients the wild type of the gene KIT (p= 0.003154). Median progression free survival in patients with disseminated GIST with mutations in exon 11 of the gene KIT, in exon 9 of the gene KIT and the wild type of the gene KIT was respectively: 5 months (95% CI 4 - 6), 20 months (95% CI 18 - 24) (p=0.0001), 22 months (95% CI 6 - 25) (p=0.00013). Median overall survival in patients with disseminated GIST with mutations in exon 11 of the gene KIT, in exon 9 of the gene KIT and with wild type of the gene KIT was respectively; 13 months (95% CI 12-18), 42 months (95% CI 20 - not reached) (p=0.0001), 41 months (95% CI 22 - not reached) (p=0.0001).

Keywords:gastrointestinal stromal tumors, GIST, sunitinib, gene KIT